This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-squamous non-small cell lung cancer by assessing the treatment response, neurological symptoms and quality of life.~Patients will receive Bevacizumab(7.5mg/kg, q3w, i.v.) before and after FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases with Bevacizumab (7.5mg/kg, q3w, IV). The primary end point is the objective response rate. The secondary end points are 1-y iPFS, 1-y PFS, 1-y OS, perilesional edema of brain metastases, neurological symptoms, quality of life and safety of the treatment.
This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-squamous non-small cell lung cancer by assessing the treatment response, perilesional edema, neurological symptoms and quality of life.